AUGUST 26, 2015 (Wednesday) 07h00 – 07h50 Meet the Professor Sessions: Mary Flowers - How I treat C-GVHD 08h00 – 08h45 Welcome and Opening Session 08h00 – 08h10 Welcome 08h10 – 08h45 Opening Plenary Session: Mary Horowitz - Current State of Transplantation and Future Perspectives 08h45 – 10h00 Scientific Session: Long term follow up after transplant: Facing our Greatest Challenge 08h45 – 09h10 Afonso Vigorito - Recommendation for Long-term survival after allogeneic HSCT: a way to improve quality of life 09h10 – 09h35 Mary Flowers - Second solid cancers after allogeneic HSCT. 09h35 – 10h00 Gerard Socie - Risk factors for late complications after HSCT 10h00 – 10h30 Coffee Break 10h30 – 11h05 Plenary Session: Robert Peter Gale - Measuring minimal residual disease before and after transplant: is it important? 11h05 – 12h20 Scientific Session: Infectious complications after HSCT 11h05 – 11h30 Clarisse Machado- Recent advances in diagnosis and treatment of viral infections after HSCT 11h30 – 11h55 Clovis Cunha - Increasing incidence of multi-resistant bacteria infections: How to prevent and treat? 11h55 – 12h20 Ray Hachem - Emerging fungal infections after HSCT 12h20 – 14h00 Lunch 14h00 – 18h00 Workshop: Minimal Residual Disease Chair: Mariester Malvezzi and Alberto Orfao 14h00 – 14h35 (Room 1) Plenary Session: Vanderson Rocha - Alternative donor HSCT for older patients with AML using IV Busulfan in the conditioning regimen: outcomes and risk factors. 14h00 – 14h35 (Room 2) Plenary Session: Regis Peffault de Latour - Alternative donor transplantation for children and adolescents with Aplastic Anemia 14h40 – 15h55 (Room 1) Pediatric Session: Acute Leukemias - Current Strategies to improve outcome after HSCT 14h40 – 15h05 Adriana Seber- Outcome of children submitted to HSCT for Acute Leukemias in Brazil: How are we doing in 2015? 15h05 – 15h30 Christina Peters - Monitoring of MRD after Allo HSCT in relapsed childhood ALL: How often? How to treat? 15h30 – 15h55 Mary Eapen - Bone marrow or peripheral blood: does it still matter for children and adolescents with malignant diseases? 14h40 – 15h55 (Room 2) Adult Session: Chronic Myeloproliferative Disorders: Point/counterpoint: What is the best preparatory regimen for patients with Myelofibrosis? 14h40 – 14h50 Vaneuza Funke - Introduction 14h50 – 15h15 Nicolaus Kroger - Reduced intensity regimens 15h15 – 15h40 Marcos de Lima - Myeloablative regimens 15h40 – 16h00 Discussion 16h00 – 16h30 Coffee Break 16h30 – 17h55 (Room 1) Pediatric Session: HSCT for nonmalignant diseases 16h30 – 16h50 Regis Peffault de Latour - EBMT experience: HSCT for inherited Bone Marrow Failure Syndromes (Fanconi Anemia and Dyskeratosis Congenita) 16h50 – 17h10 Mary Eapen - Alternative donor transplantation for non malignant diseases in pediatric patients: stem cell source and compatibility matters 17h10 – 17h30 Carmem Bonfim- Post transplantation Cyclophosphamide as a platform for HSCT in nonmalignant diseases
Transcript
AUGUST 26, 2015 (Wednesday) 07h00 – 07h50 Meet the Professor Sessions: Mary Flowers - How I treat C-GVHD
08h00 – 08h45 Welcome and Opening Session
08h00 – 08h10 Welcome
08h10 – 08h45 Opening Plenary Session: Mary Horowitz - Current State of Transplantation and Future Perspectives 08h45 – 10h00 Scientific Session: Long term follow up after transplant: Facing our Greatest Challenge 08h45 – 09h10 Afonso Vigorito - Recommendation for Long-term survival after allogeneic HSCT: a way to improve quality of life 09h10 – 09h35 Mary Flowers - Second solid cancers after allogeneic HSCT. 09h35 – 10h00 Gerard Socie - Risk factors for late complications after HSCT
10h00 – 10h30 Coffee Break
10h30 – 11h05 Plenary Session: Robert Peter Gale - Measuring minimal residual disease before and after transplant: is it important?
11h05 – 12h20 Scientific Session: Infectious complications after HSCT 11h05 – 11h30 Clarisse Machado- Recent advances in diagnosis and treatment of viral infections after HSCT 11h30 – 11h55 Clovis Cunha - Increasing incidence of multi-resistant bacteria infections: How to prevent and treat? 11h55 – 12h20 Ray Hachem - Emerging fungal infections after HSCT
12h20 – 14h00 Lunch
14h00 – 18h00 Workshop: Minimal Residual Disease Chair: Mariester Malvezzi and Alberto Orfao 14h00 – 14h35 (Room 1) Plenary Session: Vanderson Rocha - Alternative donor HSCT for older patients with AML using IV
Busulfan in the conditioning regimen: outcomes and risk factors. 14h00 – 14h35 (Room 2) Plenary Session: Regis Peffault de Latour - Alternative donor transplantation for children and
adolescents with Aplastic Anemia
14h40 – 15h55 (Room 1) Pediatric Session: Acute Leukemias - Current Strategies to improve outcome after HSCT 14h40 – 15h05 Adriana Seber- Outcome of children submitted to HSCT for Acute Leukemias in Brazil: How are we doing in 2015? 15h05 – 15h30 Christina Peters - Monitoring of MRD after Allo HSCT in relapsed childhood ALL: How often? How to treat? 15h30 – 15h55 Mary Eapen - Bone marrow or peripheral blood: does it still matter for children and adolescents with malignant
diseases?
14h40 – 15h55 (Room 2) Adult Session: Chronic Myeloproliferative Disorders: Point/counterpoint: What is the best preparatory regimen for patients with Myelofibrosis? 14h40 – 14h50 Vaneuza Funke - Introduction 14h50 – 15h15 Nicolaus Kroger - Reduced intensity regimens 15h15 – 15h40 Marcos de Lima - Myeloablative regimens 15h40 – 16h00 Discussion
16h00 – 16h30 Coffee Break
16h30 – 17h55 (Room 1) Pediatric Session: HSCT for nonmalignant diseases 16h30 – 16h50 Regis Peffault de Latour - EBMT experience: HSCT for inherited Bone Marrow Failure Syndromes (Fanconi Anemia
and Dyskeratosis Congenita) 16h50 – 17h10 Mary Eapen - Alternative donor transplantation for non malignant diseases in pediatric patients: stem cell source
and compatibility matters 17h10 – 17h30 Carmem Bonfim- Post transplantation Cyclophosphamide as a platform for HSCT in nonmalignant diseases
16h30 – 17h55 (Room 2) Adult Session: HSCT for patients with Chronic Lymphocytic leukemias 16h30 – 16h55 Fabio Kerbauy - The Brazilian Experience 16h55 – 17h20 Robert Peter Gale - Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or
novel agents? 17h20 – 17h55 Renier Brentjens - CAR therapy for B Cell Malignancies
AUGUST 27, 2015 (Thursday) 07h00 – 08h00 Leo Luznik - Meet the Professor Sessions: How to do Haplos with post transplant CY? 08h10-08h45 Plenary Session: Anna Sureda - Refractory Hodgkin Lymphoma after autologous transplantation: what are the
best options?
08h45 – 10h00 Scientific Sessions: Aplastic Anemia 08h45 – 09h10 Rodrigo Calado - New insights in the biology of aplastic Anemia 09h10 – 09h35 Ricardo Pasquini - Late rejection after HSCT for aplastic anemia 09h35 – 10h00 Gerard Socie - EBMT experience on HSCT for patients with Aplastic Anemia 10h00 – 10h30 Coffee Break and visit to Exhibitors
10h30 – 11h05 (Room 1) Plenary Session: Mary Flowers - From Classification to therapy: Current issues in C-GVHD
10h30– 11h05 (Room 2) Plenary Session: Maria Carolina Oliveira - Stem Cell transplantation for auto-immune diseases: Patient Selection, stem cell mobilization, preparatory regimens and supportive care.
11h05 – 12h20 Scientific Session: Acute Leukemias 11h05 – 11h30 Alberto Orfao - Minimal residual disease detection in ALL: technical approaches and clinical applications 11h30 – 11h55 Robert Peter Gale - Who with AML should have a transplant in 1
st remission?
11h55 – 12h20 Nelson Hamerschlak - Hematopoietic Stem Cell Transplantation for AML. The Brazilian experience
16h00 – 16h30 Coffee Break and visit to Exhibitors
16h30 – 17h30 (Room 1) Pediatric Session: Preparatory regimens 16h30 – 16h50 Christina Peters - The use of Treosulfan in the preparatory regimen of children and adolescents with pediatric
malignancies. 16h50 – 17h10 Vanderson Rocha - Is TBI necessary for HSCT in patients with Acute Lymphoblastic Leukemias? 17h10 – 17h30 Ray Hachem - Anti fungal and anti bacterial prophylaxis: what is the best strategy for pediatric patients submitted to
allogeneic transplantation?
16h30 – 17h30 (Room 2) Adult Session: Multiple Myeloma: Novel agents for transplantation and future directions 16h30 – 16h50 Alberto Orfao - Flow Minimal residual Disease in multiple myeloma: Towards standardization of high sensitive
disease monitoring 16h50 – 17h10 Marcelo Pasquini -The role of novel agents as consolidation and maintenance therapy following autologous stem
cell transplantation 17h10 – 17h30 Angelo Maiolino - Brazilian experience: Should All Transplant-Eligible Patients Receive Early autologous stem cell
transplantation?
17h30 – 18h30 SBTMO General Assembly
AUGUST 28, 2015 (Friday)
07h00 – 08h00 (Room 1) Meet the Professor Sessions: Sergio Giralt - Myelodysplastic syndrome and Stem cell transplantation:
what you always wanted to know but was afraid to ask! 07h00 – 08h00 (Room 2) Meet the Professor Sessions: Raul Ribeiro - Acute leukemias and indication for HSCT: what are the
controversies? 08h10 – 08h45 Plenary Session: Renier Brentjens - Novel cellular therapies for leukemias: how do CARs work?
08h45 – 10h00 Joint Scientific Sessions: SBTMO/LABMT/ CIBMTR 08h45 – 09h10 Adriana Seber - What is new in LABMT and why it is important. 09h10 – 09h35 Francisco Barriga - Access to HSCT in Latin America 09h35 –10h00 Mary Horowitz - Latin America collaboration with the CIBMTR
10h00 - 10h30 Coffee Break
10h30 – 12h20 Joint Scientific Sessions: HLA/SBTMO: 10h30 – 10h40 Nelson Hamerschlak - Haploidentical transplantation in Brazil: Current scenario and future perspectives 10h40 – 11h20 Leo Luznik - Who is the best donor for a haplo mismatched transplant? 11h20 – 11h50 Howard Gebel - When and how the presence of HLA specific antibodies should change donor’s choice. 11h50 –12h20 Douglas Gladstone - Partially mismatched transplantation and HLA donor specific antibodies - desensitization
14h00 – 14h35 (Room 1) Plenary Session: Anders Fasth - Immune recovery after Pediatric HSCT
14h00 – 14h35 (Room 2) Plenary Session: Marcos de Lima - Timing and patient selection for transplantation in Myelodysplastic Syndrome
14h40 – 15h55 (Room 1) Pediatric Session: Malignant diseases 14h40 – 15h05 Amin Alousi - Allogeneic Stem cell transplantation for children with acute Leukemias: Is there a balance between
GVHD and relapse? 15h05 – 15h30 Christina Peters - HSCT for patients with pediatric non-Hodgkin lymphomas 15h30 – 15h55 Raul Ribeiro - How to get your AML patient into remission prior to transplant?
14h40 – 15h55 (Sala 2) Adult Session: Non-Hodgkin Lymphomas: 14h40 – 15h05 Peter Johnson - Non-transplant approaches in the treatment of Non-Hodgkin Lymphomas 15h05 – 15h30 Anna Sureda - What is the role of autologous and allogeneic SCT in Non-Hodgkin Lymphomas? 15h30 – 15h55 Marcelo Pasquini- Are all conditioning regimens for Lymphoma the same?
16h00 – 16h30 Coffee Break and visit to the exhibitors
16h30 – 17h55 (Room 1) Pediatric Session: Challenges for Pediatric HSCT in Brazil and Latin America 16h30 – 16h55 Anders Fasth - New indications for HSCT in primary immunodeficiencies: How to transplant these patients? 16h55 – 17h20 Juliana Fernandes - Transplantation for metabolic diseases in Brazil: Considerations and challenges 17h20 – 17h55 Luis Darrigo - Stem Cell Transplantation for patients with Hemoglobinopathies: The Brazilian Experience
16h30 – 17h55 (Room 2) Adult Session: HSCT for adults with Leukemia: challenges and controversies 16h55 – 17h20 Belinda Simoes - New strategies in the treatment of Ph1+ ALL 16h55 – 17h20 Nicolaus Kroger - Is there sufficient evidence to support HCT in older adults with Acute Leukemias? 17h20 – 17h55 Hans Jochem Kolb - How to improve outcome after HSCT for AML?
20h00 SBTMO party
AUGUST 29, 2015 (Saturday) 08h10 – 08h45 Plenary Session: Luis Fernando Bouzas - REDOME/BRASILCORD: Current status, challenges and future perspectives.
08h45 – 10h00 Scientific Sessions: Alternative Donor Transplantation for adults with malignancies: and the winner is… 08h45 – 09h10 Vanderson Rocha- Cord Blood Transplants 09h10 – 09h35 Mary Eapen - Mismatched unrelated donor 09h35 – 10h00 Leo Luznik - Mismatched related donors with post transplant Cyclophosphamide
10h00 – 10h30 Coffee Break
10h30 – 12h20 Scientific Sessions: Strategies to prevent relapse following allo SCT for acute leukemia – 2015 perspective 10h30 – 10h55 Sergio Giralt -How to improve survival and decrease relapse in patients transplanted with advanced diseases? 10h55 – 11h20 Hans Jochem Kolb - Cellular therapies for the treatment of relapse after HSCT. 11h20 – 11h55 Marcos de Lima - Are we changing the scope of AML relapse post allo SCT by hypometilating agents?
11h55 – 12h30 Closing Plenary Session: Sergio Giralt : Hematopoietic Cell Transplantation in the Era of Universal Donor Availability: Current perspective
1- STATISTICS AND HEMATOPOETIC STEM CELL TRANSPLANTATION: WHAT DO WE NEED TO KNOW? Brent Logan, Marcelo Pasquini, Mary Eapen, Mary Horovitz and Vanderson Rocha
Hora Tema Palestrante
8:30-8:45 Introduction Pasquini
9:00-9:15 First project A confirmar
9:15-9:45 Getting started: How to plan the study? Eapen
9:45-10:15 Analysis Logan
10:15-10:45 Break -
10:45-11:00 Second project A confirmar
11:00-11:30 Analysis Logan
11:30-12:00 Interpretation and next steps Horowitz
